Partner William McConagha and associate Amela Amaechi look at the FDA's response to the COVID-19 pandemic, including its focus on the emergency review of promising therapies, as well as on bogus treatments and misleading COVID-19 claims.
Product Safety Risks Are a Circular Challenge for Pharmaceutical Companies
Stericycle's 2020 Recall Index: Second Edition